BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marafini I, Monteleone G. Inflammatory bowel disease: new therapies from antisense oligonucleotides. Ann Med 2018;50:361-70. [PMID: 29911450 DOI: 10.1080/07853890.2018.1490025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Marafini I, Troncone E, Salvatori S, Monteleone G. TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases. Pharmacol Res 2020;155:104757. [PMID: 32194176 DOI: 10.1016/j.phrs.2020.104757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Duan B, Li M, Sun Y, Zou S, Xu X. Orally Delivered Antisense Oligodeoxyribonucleotides of TNF-α via Polysaccharide-Based Nanocomposites Targeting Intestinal Inflammation. Adv Healthc Mater 2019;8:e1801389. [PMID: 30714345 DOI: 10.1002/adhm.201801389] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
3 Chen K, Lou Y, Zhu Y. Tong Xie Yao Fang: A Classic Chinese Medicine Prescription with Potential for the Treatment of Ulcerative Colitis. Evid Based Complement Alternat Med 2021;2021:5548764. [PMID: 34211567 DOI: 10.1155/2021/5548764] [Reference Citation Analysis]
4 Faber S, Lahoti T, Taylor E, Lewis L, Sapiro J, Toledo Sales V, Dragan Y, Jeffy B. Current Therapeutic Landscape and Safety Roadmap for Targeting the Aryl Hydrocarbon Receptor in Inflammatory Gastrointestinal Indications. Cells 2022;11:1708. [DOI: 10.3390/cells11101708] [Reference Citation Analysis]
5 Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JGW. Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics 2020;12:E539. [PMID: 32545207 DOI: 10.3390/pharmaceutics12060539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
6 Scarozza P, Schmitt H, Monteleone G, Neurath MF, Atreya R. Oligonucleotides-A Novel Promising Therapeutic Option for IBD. Front Pharmacol 2019;10:314. [PMID: 31068803 DOI: 10.3389/fphar.2019.00314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
7 Deprey K, Batistatou N, Debets MF, Godfrey J, VanderWall KB, Miles RR, Shehaj L, Guo J, Andreucci A, Kandasamy P, Lu G, Shimizu M, Vargeese C, Kritzer JA. Quantitative Measurement of Cytosolic and Nuclear Penetration of Oligonucleotide Therapeutics. ACS Chem Biol 2022;17:348-60. [PMID: 35034446 DOI: 10.1021/acschembio.1c00830] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Laudisi F, Cherubini F, Di Grazia A, Dinallo V, Di Fusco D, Franzè E, Ortenzi A, Salvatori I, Scaricamazza S, Monteleone I, Sakamoto N, Monteleone G, Stolfi C. Progranulin sustains STAT3 hyper-activation and oncogenic function in colorectal cancer cells. Mol Oncol 2019;13:2142-59. [PMID: 31361391 DOI: 10.1002/1878-0261.12552] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]